Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camlipixant (BLU-5937) in Refractory Chronic Cough
NCT04678206Phase 2Completed
- Sponsor
- GSK
- Start
- Dec 2020
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of camlipixant in refractory chronic cough (RCC), sponsored by GSK. Started Dec 2020; status: completed.
02
Drugs
camlipixant
03
Conditions
refractory chronic cough (RCC)
Beyond the preview
Go deeper on NCT04678206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04678206.